Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.11 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 619.75K shares.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.49M shares, a 192.90% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 47.22K shares, a 98.27% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.73M shares, a 248.83% increase from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 783.37K shares, a 31.53% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.14M shares, a 34.29% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 619.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 3.11M shares 10-Q · filed 2026-08-04 | 3.11M shares derived: sum of 3 quarters · filed 2026-08-04 | 3.11M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 2.49M shares 10-Q · filed 2026-05-15 | 2.49M shares derived: sum of 2 quarters · filed 2026-05-15 | 2.49M shares derived: sum of 3 quarters · filed 2026-05-15 | 1.69M shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-30 | -802.28K shares derived: sum of 3 quarters · filed 2026-03-30 | 47.22K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -802.28K shares derived: sum of 2 quarters · filed 2025-11-14 | 47.22K shares 10-Q · filed 2025-11-14 | 1.07M shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | -802.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 47.22K shares 10-Q · filed 2025-08-05 | 1.07M shares derived: sum of 3 quarters · filed 2025-08-05 | 1.18M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 849.50K shares 10-Q · filed 2025-05-06 | 1.87M shares derived: sum of 2 quarters · filed 2025-05-06 | 1.98M shares derived: sum of 3 quarters · filed 2025-05-06 | 2.16M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 1.02M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 1.13M shares derived: sum of 2 quarters · filed 2025-03-28 | 1.31M shares derived: sum of 3 quarters · filed 2025-03-28 | 2.73M shares 10-K · filed 2025-03-28 |
| 2024-09-30 | 116.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 293.07K shares derived: sum of 2 quarters · filed 2024-11-14 | 1.71M shares 10-Q · filed 2024-11-14 | 1.84M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 177.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 1.60M shares 10-Q · filed 2024-08-06 | 1.72M shares derived: sum of 3 quarters · filed 2024-08-06 | 1.87M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 1.42M shares 10-Q · filed 2024-05-09 | 1.55M shares derived: sum of 2 quarters · filed 2024-05-09 | 1.70M shares derived: sum of 3 quarters · filed 2024-05-09 | 1.70M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 125.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 274.40K shares derived: sum of 2 quarters · filed 2024-02-29 | 279.40K shares derived: sum of 3 quarters · filed 2024-02-29 | 783.37K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 149.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 154.40K shares derived: sum of 2 quarters · filed 2023-11-07 | 658.37K shares 10-Q · filed 2023-11-07 | 686.87K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 5.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 508.97K shares 10-Q · filed 2023-08-03 | 537.47K shares derived: sum of 3 quarters · filed 2023-08-03 | 653.47K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 503.97K shares 10-Q · filed 2023-05-09 | 532.47K shares derived: sum of 2 quarters · filed 2023-05-09 | 648.47K shares derived: sum of 3 quarters · filed 2023-05-09 | 966.32K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 28.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 144.50K shares derived: sum of 2 quarters · filed 2023-03-29 | 462.35K shares derived: sum of 3 quarters · filed 2023-03-29 | 1.14M shares 10-K · filed 2023-03-29 |
| 2022-09-30 | 116.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 433.85K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.12M shares 10-Q · filed 2022-11-08 | 1.24M shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-06-30 | 317.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 999.55K shares 10-Q · filed 2022-08-09 | 1.12M shares derived: sum of 3 quarters · filed 2023-03-29 | 1.21M shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | 681.70K shares 10-Q · filed 2022-05-10 | 802.70K shares derived: sum of 2 quarters · filed 2023-03-29 | 893.37K shares derived: sum of 3 quarters · filed 2023-03-29 | 1.17M shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | 121.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 211.67K shares derived: sum of 2 quarters · filed 2023-03-29 | 487.33K shares derived: sum of 3 quarters · filed 2023-03-29 | 1.74M shares 10-K · filed 2023-03-29 |
| 2021-09-30 | 90.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 366.33K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.62M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 275.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 1.53M shares 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | 1.25M shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 1.90M shares 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |